Mineralys Therapeutics, Inc.
RADNOR, PA · Founded 2019 · CIK 0001933414 · Biotech · Public
Aldosterone antagonist therapeutics for hypertension and chronic kidney disease
mineralystx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $118M
- 1 Form D · Jun 2022
- 52 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 0 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $117,999,994 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2813 | Interius BioTherapeutics | — | $118M |
| 2814 | TAMBO, INC. | — | — |
| 2815 | Diapin Therapeutics LLC | — | — |
| 2816 | Mineralys Therapeutics, Inc. | — | $118M |
| 2817 | LYST THERAPEUTICS LLC | — | — |
| 2818 | Relation Therapeutics | — | $116M |
| 2819 | STEL Technologies, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Srinivas AkkarajuDirector
- Alexander AsamDirector
- Jon CongletonDirector · Executive Officer
- Derek DiRoccoDirector
- Adam LevyExecutive Officer
- Olivier LitzkaDirector
- Takeshi TakahashiDirector
- Brian Taylor SlingsbyDirector
Patents
- Methods Of Treating Hypertension With A Combination Of An Aldosterone Synthase Inhibitor And A Diureticapplication
- Methods Of Treating Hypertension In Obese Subjectsapplication
- CYP11B2 Beta Hydroxylase Inhibitors For Hypertensionapplication
- Methods Of Treating Chronic Kidney Disease (ckd) Or Ckd And Hypertension With Lorundrostat, Or A Combination Of Lorundrostat And A SGLT2 Inhibitorapplication
- Methods Of Treating Hypertension In Obese Subjectsapplication
- Methods Of Treating Hypertension With A Combination Of An Aldosterone Synthase Inhibitor And A Diureticapplication
- CYP11B2 Beta Hydroxylase Inhibitors For Hypertensionapplication
- CYP11B2 Beta Hydroxylase Inhibitors For Hypertensionapplication
- Methods Of Treating Hypertension With A Combination Of Lorundrostat And Two Or More Anti-hypertensive Medicationsapplication
- Methods Of Treating Chronic Kidney Disease (ckd) Or Ckd And Hypertension With Lorundrostat, Or A Combination Of Lorundrostat And A SGLT2 Inhibitorapplication
- Process For Producing Triazine Compoundapplication
- Methods Of Treating Hypertension With A Combination Of Lorundrostat And Two Or More Anti-hypertensive Medicationsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.